Micellar nanoparticles (NPs) based on linear polyethylene glycol (PEG)-block-dendritic cholic acids (CA) copolymers (telodendrimers), for the targeted delivery of chemotherapeutic drugs in the treatment of cancers, are reported. The micellar NPs have been decorated with a high-affinity "OA02" peptide against alpha-3 integrin receptor to improve the tumor targeting specificity which is overexpressed on the surface of ovarian cancer cells. "Click chemistry" was used to conjugate alkyne-containing OA02 peptide to the azide group at the distal terminus of the PEG chain in a representative PEG 
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Introduction
Ovarian cancer is the ninth most common cancer, with an estimated 21,990 new cases in 2011, but is the fifth most deadly, with an estimated 15,460 deaths in 2011 (1). The standard treatment for patients with advanced-stage disease usually involves surgical staging and debulking followed by adjuvant chemotherapy, typically with platinum and paclitaxel (PTX). However, the more extensive use of chemotherapeutic drugs such as PTX is often limited by its severe side effects, including hypersensitivity reactions, myelosuppression and neurotoxicity, which may be attributed to their nonspecific systemic organ distribution and inadequate intra-tumor concentrations, resulting in suboptimal efficacy (2, 3) . Despite the intensive chemotherapy, over 70% of ovarian cancer patients will suffer from disease relapse or recurrence, and ultimately die of this disease. Therefore, there is a tremendous incentive to refine existing treatment modalities to avoid or delay the recurrence and to treat recurrent ovarian cancer more effectively. Optimization of chemotherapeutic drug delivery is among the critical approaches to improve the therapeutic index of cytotoxic agents.
Nanotechnology is an emerging field that has shown great promise in the development of novel diagnostic and therapeutic agents for a variety of diseases, including cancers (4) . As the vasculature in tumors is known to be leaky, and the tumor lymphatic system is also deficient, nanoparticles (NPs) can preferentially accumulate in the tumor site via the enhanced permeability and retention (EPR) effects (5) .
Polymeric micelles represent one of the most promising nanocarriers due to their unique core-shell structure formed by amphiphilic block copolymers, which could facilitate the solublization of poorly soluble drugs and protect the drugs from degradation and metabolism. We have recently developed a series of novel linear-dendritic block copolymers (telodendrimers) comprising polyethylene glycol (PEG) and dendritic cholic acids (CA), which can encapsulate high concentrations of hydrophobic drugs such as PTX and self-assemble to form stable core-shell micelles under aqueous condition (6) (7) (8) (9) (10) (11) (12) superior anti-tumor efficacy and toxicity profile compared to free drug (Taxol ® ) and PTX/human serum albumin nanoaggregate (Abraxane ® ) at equivalent PTX doses, in nude mice bearing human ovarian cancer (SKOV-3) xenografts (6) .
To further facilitate the residence, penetration, and cancer cell uptake of delivered drugs within the tumor sites for more efficient cancer treatment, an attractive approach is to decorate the NPs surface with targeting ligands that specifically recognize receptors on cancer cells (active targeting). Active targeting might result in higher retention of NPs drugs at tumor sites (i.e., by reducing passive transport away from tumor) and enhanced uptake of the drugs by cancer cells via receptor-mediated endocytosis (13) (14) (15) . Furthermore, actively targeted NPs have also shown the potential to overcome multidrug resistance (MDR) via bypassing of P-glycoprotein mediated drug efflux (16) . Combining passive and active targeting in a single platform will further improve the therapeutic index of nanocarrier delivered drugs (17, 18) . A wide variety of targeting ligands, including antibodies and single-chain Fv fragment (19, 20) , peptides (21, 22) , small molecules (23) , and aptamers (24, 25) have been used with varying degrees of success to functionalize NPs for their potential application in targeted cancer therapy.
Although antibodies or antibody fragments are effective as targeting agents, there are some innate problems such as decreased receptor affinity as a result of conjugation methods, potential immunogenicity, nonspecific uptake by reticuloendothelial system (RES) and relative poor stability (17) .
In contrast, peptides or peptidomimetics with high binding affinity and specificity to cancer cells may have many favorable characteristics, including deep tumor penetration due to the smaller size, lack of immunogenicity, easy synthesis and scale-up, and good stability especially if D-configuration and unnatural amino acids are used (26) .
Integrins are a family of heterodimeric transmembrane glycoproteins involved in a wide range of cell-to-extracellular matrix (ECM) and cell-to-cell interactions (27, 28) . It has been found that integrins are overexpressed on various cell types such as angiogenic endothelial cells and certain cancer cells. For example, alpha-3 integrin is overexpressed in several types of cancers, especially ovarian cancer, breast cancer, and melanoma (29) . The overexpression of alpha-3 integrin on these cancer cells has been exploited as a promising pharmacological target for the selective drug delivery in the treatment of these cancers. Additionally, during the cell locomotion and migration, integrins can undergo endocytosis after the activation with anchoring ligands, which may facilitate the intracellular delivery of NPs drugs into cancer cells, when these NPs are decorated with integrin-targeting ligands. A high-affinity alpha-3 integrin targeting peptide "OA02" has been identified in our laboratory through screening one-bead one-compound (OBOC) combinatorial peptide libraries (30) . This "OA02" peptide has been shown to bind strongly to alpha-3 integrin overexpressing ovarian cancer cells and specifically target ovarian cancer xenografts (ES-2) in nude mice when conjugated to near-infrared fluorescence (NIRF) dyes (30) .
In the present study, we hypothesize that the incorporation of "OA02" peptide ligand onto our newly developed micellar NPs, will facilitate the precise homing of drug payload to alpha-3 integrin overexpressing ovarian cancer cells. First, the alkyne-modified "OA02" peptide was synthesized and conjugated to the azide-functionalized PEG 
Materials and Methods
Materials. Diamino polyethylene glycol was purchased from Rapp Polymere (Tübingen, Germany). Synthesis of OA02 conjugated PEG 5k -CA 8 telodendrimer. Boc-NH-PEG 5k -CA 8 telodendrimer was first synthesized as described previously (6) . CD31 primary antibody (Millipore, 1:100) for 1 h, and Cy3 conjugated goat anti-rat IgG secondary antibody (Millipore, 1:1500) for 1 h at room temperature. (Figure 2A ) demonstrated that PTX-OA02-NPs were spherical, with uniform particle sizes of around 50 nm in diameter, which was similar with the result obtained from DLS measurement ( Figure 2B ). The zeta potential of PTX-OA02-NPs in PBS was almost neutral (-0.64 mV). The stability of PTX-OA02-NPs was evaluated by measuring the changes of particle sizes over time at different conditions. PTX-OA02-NPs were found to be very stable at 4 °C for over 3 months, and also stable at 37 °C for at least 72 h when incubated with 50% FBS (data not shown), which indicated that they will likely be able to maintain their stability and integrity during their in vivo applications. The drug release pattern from PTX-OA02-NPs was similar with that from PTXNPs, which both were biphasic, with the initial rapid release of PTX during the first 4 h, followed by the slow linear release over the subsequent few days ( Figure 2C ). In summary, the decoration of OA02 peptide had negligible impact on the physicochemical properties of PEG 5k -CA 8 NPs, including CMC, morphology, particle size, drug loading capacity, encapsulation efficiency, stability and drug release profile. This is probably because the OA02 peptide conjugation occurs at the distal end of PEG chain which is located on the shell of self-assembled micellar NPs without interfering with the drug-holding hydrophobic core unit. Figure S-4) . The uptake profiles of FITClabeled OA02-NPs in ovarian cancer cells were first qualitatively observed by the confocal microscopy.
Cellular uptake studies. Alpha-3 integrin was demonstrated to be overexpressed on both SKOV-3 and ES-2 cells, as measured by the flow cytometric analysis (
Non-targeted NPs had minimal non-specific cellular uptake after 2-h incubation, whereas the decoration of OA02 peptide greatly increased the extent of NPs uptake in both SKOV-3 ( Figure 3A ) and ES-2 cells (Figure S-5A ). Most FTIC-labeled NPs (green) distributed around the perinuclear region, which meant that these NPs were internalized into the cytoplasm. More importantly, the uptake of OA02-NPs in both ovarian cancer cells was able to be remarkably inhibited by excess amount of alpha-3 integrin antibody or free OA02 peptide, suggesting the alpha-3 integrin receptor-dependent internalization of OA02-NPs.
The uptake efficiencies of FITC-labeled OA02-NPs in ovarian cancer cells and K562 leukemia cells (alpha-3 integrin negative) were further quantitatively measured by the flow cytometric analysis.
Both non-targeted NPs and OA02-NPs had similar low nonspecific uptake in K562 cells ( Figure 3B ).
However, OA02-NPs exhibited significantly higher uptake than the non-targeted NPs in both ovarian cancer cells (P < 0.05), with almost 6-fold higher uptake in SKOV-3 cells ( Figure 3C ) and 4-fold higher uptake in ES-2 cells (Figure S-5B) , respectively. The addition of free OA02 peptide was able to inhibit the uptake of OA02-NPs in SKOV-3 cells ( Figure 3D dependent manner, further confirming the alpha-3 integrin targeting specificity of OA02-NPs. It should be noted that significant higher concentration of free peptide (10 to 100-folds) was required to inhibit the cellular uptake of OA02-NPs, while the equal concentration of free peptide did not produce obvious inhibition effect. This could be possibly explained by the increased binding affinity of OA02 peptides presented on the NPs surface due to the multivalency effects (35) . the intravenous injection, and gradually accumulated into the SKOV3-luc tumor. However, the uptake rate of OA02-NPs in the tumor site was faster than that of non-targeted NPs. Substantial contrast between tumors and background in the mice injected with OA02-NPs was observed at around 4 h postinjection and these NPs were able to be retained in the tumor throughout the 24-h period, whereas the accumulation of non-targeted NPs in the tumor was not apparent until 8 h post-injection ( Figure 5A ). Ex vivo images at 24 h demonstrated that both non-targeted NPs and OA02-NPs exhibited relatively high uptake in the SKOV3-luc tumor compared to normal organs except the liver (macrophage uptake), as the result of EPR effect ( Figure 5B) . However, the median fluorescence intensity (MFI) of tumors for OA02-NPs was approximately 1.7-fold higher than that for non-targeted NPs ( Figure 5C , P < 0.05). The histological distribution of NPs in the tumor tissue was further observed under the confocal microscopy.
Intracellular
As shown in Figure 5D , the majority of Cy5.5-labeled non-targeted NPs (red) were mainly distributed in the perivascular region, which is in concordance with previous histological observations of passive accumulation of liposomes and micelles in tumor tissues (14) . In contrast, OA02-NPs were able to (33) . In addition, this group of mice was found to have significant amount of body weight loss (with a nadir of 6.7%) after receiving the first few doses, when compared to the control group (P < 0.05).
In contrast, the mice in both PTX-NPs and PTX-OA02-NPs groups tolerated the regimens well. The treatments did not seem to have obvious adverse impact on their activity level and body weight ( Figure   6C ). Overall, the PTX nanoformulations, both PTX-NPs and PTX-OA02-NPs, demonstrated with an improved systemic toxicity profile, which might be attributed to their Cremophor-free composition, prolonged blood retention time and sustained drug release features (40) .
Conclusion
We have successfully developed OA02 peptide-targeted polymeric micelles system to effectively deliver chemotherapeutic drugs to ovarian cancer. High-affinity and high-specificity "OA02" peptide against alpha-3 integrin was successfully conjugated to the distal PEG terminus of PEG 5k -CA 8 telodendrimer via "click chemistry", and displayed on the surface of self-assembled micellar NPs. 
